Neovacs SA of France has reported promising data from a Phase 2a study of a new immunotherapy for patients with rheumatoid arthritis who have ceased to respond to an anti-tumour necrosis factor-alpha (TNF-alpha) monoclonal antibody. ---Subscribe to MedNous to access this article--- Research & University News Company News
